{"brief_title": "This is an Early Study to Investigate the Effect of Gimatecan\u00ae in Adults With Solid Tumor", "brief_summary": "Gimatecan\u00ae is sigma-tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors. We are conducting this study to determine the Maximum Tolerated Dose of our compound, when given as a capsule, rather than by intravenous injection.", "condition": "Solid Malignancies", "intervention_type": "Drug", "intervention_name": "Gimatecan\u00ae (ST-1481)", "criteria": "Inclusion criteria: - Histologically/cytologically proven advanced solid tumors - Life expectancy of at least 3 months with normal hematological, liver and renal function Exclusion criteria: - Pregnant and lactating patients - Participation in any investigating drug study within 4 weeks preceding treatment start or concurrent treatment with any other anti-cancer therapy - Gastrointestinal dysfunction that could alter absorption or motility", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00033202.xml"}